Antenatal corticosteroid (ANCS) treatment hastens fetal lung maturity and improves survival of premature infants, but the long-term effects of ANCS are not well-described. Animal models suggest that ...

Please provide your email address to receive an email when new articles are posted on . After a hyperkalemia event, mineralocorticoid receptor antagonists were discontinued in up to 46% of patients.

Propranolol’s mechanism of action for controlling infantile hemangioma (IH) remains unclear. We hypothesize that this nonselective beta antagonist downregulates renin–angiotensin–aldosterone (RAA) ...

A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well ...

Objectives: This study examined renin-angiotensin-aldosterone system (RAAS) inhibitor dose levels in a US patient population and investigated the impact of hyperkalemia on RAAS inhibitor dose and the ...

Background Altitude training produces advantages over sea level training, but athletes require acclimatization to avoid discomfort or mountain sickness, in which the blood pressure control is ...

This is a preview. Log in through your library . Abstract The pathogenesis of high-altitude pulmonary edema (HAPE) has been at least partially attributed to the local dysregulation of the ...

Evaluated renin-angiotensin-aldosterone system (RAAS) inhibitor drugs and their maximum doses, listed in descending order of observed frequency at index: lisinopril, 40 mg; losartan, 100 mg; valsartan ...

Mineralocorticoid receptor antagonists (MRAs) are still finding their place in nephrology. Many of us relegate them to the bottom of our therapeutic bag for use only after we've exhausted other ...

In trying to understand the role of prostaglandins -- a family of fatty compounds key to the cardiovascular system -- in blood pressure maintenance, researchers discovered that mice that lack the ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in ...

There is concern about the potential of an increased risk related to medications that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), ...